Immunotherapy for non-Hodgkin's lymphoma.
Humanized monoclonal anti-CD20 has impressive activity and radioimmunoconjugates. Targeting the same molecule has led to prolonged remissions in both moderate and myeloablative doses. Idiotype-based vaccination has produced an apparent prolongation in disease-free and overall survival in selected patients with follicular lymphoma. Adoptive cellular therapy is active in the setting of Epstein-Barr virus-induced lymphoma after allogenic bone marrow transplantation. Improvements in each of these developments are readily in sight.
Longo
D L
DL
National Institutes of Health, National Institute on Aging, Baltimore, MD 21224, USA.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy; D016219:Immunotherapy, Adoptive; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*
D000911:Antibodies, Monoclonal; D016207:Cytokines; D018796:Immunoconjugates